{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.7","value":"77.4"},{"groupId":"OG001","spread":"76.4","value":"132"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.1","value":"89.7"},{"groupId":"OG001","spread":"47.6","value":"143"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Measure the Cmax","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG000","title":"Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG001","title":"Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Part 1 participants who received any study drug and had evaluable Cmax data at each timepoint.","reportingStatus":"POSTED","timeFrame":"Part 1: Cycle 1 Day 1 (C1 D1), C1 D15 (Cycle = 28 days)","title":"Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Rebastinib (Part 1)","type":"SECONDARY","unitOfMeasure":"nanograms/milliliter (ng/mL)"}